Optimization of Diagnosis, Measurable Residual Disease Assessment, and Study of the Immunological Microenvironment: Towards Personalized Therapy in Acute Lymphoblastic Leukemia

Datos básicos

Código:: PRDVA246268GIL
Protocolo:: PRDVA246268GIL
EUDRACT:
NCT:
Centro:
Dotación:: 100.600,00 €
Año de incio:: 2024
Año de finalización:: 2028

RRHH NACIONAL Finan. Competitiva Privada

Documentos

No hay documentos

Participantes

Javier De La Rubia Comos

Investigador Colaborador
Eva Barragán González

Investigador Principal
Jose Vicente Gil Orti

Doctorando

Grupos

Hematología y Hemoterapia

Investigador Principal

Javier De La Rubia Comos

Financiadores - Promotores

FUNDACIÓN CIENTÍFICA AECC

Resultados del Ensayo Clínico

Publicaciones en Revistas 13

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Perez Miguez, Carlos; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2024-201407. 2024

Atypical B-Cell Acute Lymphoblastic Leukemia with iAMP21 in the Context of Constitutional Ring Chromosome 21: A Case Report and Review of the Genetic Insights.

Gil, Jose Vicente; (...); Llop, Marta

Article. 10.3390/ijms26010357. 2025

Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial

Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria

Meeting Abstract. https://doi.org/10.1182/blood-2022-162584. 2024

Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)

Segui, Ines Gomez; (...); Garma, Julio Del Rio

Meeting Abstract. 2024

Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

Eirís J; (...); Sanz J

Article. 10.1016/j.jtct.2024.10.009. 2024

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.

Article. 10.1002/hem3.70031. 2024

IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION

Eiris, Juan; (...); Balaguer-Rosello, Aitana

Meeting Abstract. 2024

Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.

Asensi Cantó P; (...); Sanz J

Article. 10.1038/s41409-024-02391-3. 2024

Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2024.12.006. 2024

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

Superior Live Birth Rates, Reducing Sperm DNA Fragmentation (SDF), and Lowering Miscarriage Rates by Using Testicular Sperm Versus Ejaculates in Intracytoplasmic Sperm Injection (ICSI) Cycles from Couples with High SDF: A Systematic Review and Meta-Analysis

Cano-Extremera, Marina; (...); Puchalt, Nicolas Garrido

Review. 10.3390/biology14020130. 2025

Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.

De la Torre EP; (...); Montesinos P

Letter. 10.3324/haematol.2023.284601. 2024